Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
Jump to:
Preferred Name | Carboprost | |
Synonyms |
|
|
Definitions |
The (15S)-15 methyl analogue of naturally occurring prostaglandin F2 alpha (PGF2 alpha) with oxytocic activity. Mimicking endogenous PGF2 alpha, carboprost activates prostaglandin F receptor, a G-protein coupled receptor, on smooth muscle cells, thereby resulting in smooth muscle contractions. When administered intramuscularly on gravid subjects, this agent induces myometrium contractions, thereby initiating luteolysis and consequently parturition. Furthermore, carboprost's action on vascular smooth muscle and gastrointestinal tract sphincters leads to raised blood pressure and induces vomiting or diarrhea, respectively. |
|
ID |
http://purl.obolibrary.org/obo/NCIT_C61662 |
|
CAS_Registry |
35700-23-3
|
|
CHEBI_ID |
CHEBI:3403
|
|
Chemical_Formula |
C21H36O5
|
|
code |
C61662
|
|
Contributing_Source |
FDA
|
|
definition |
The (15S)-15 methyl analogue of naturally occurring prostaglandin F2 alpha (PGF2 alpha) with oxytocic activity. Mimicking endogenous PGF2 alpha, carboprost activates prostaglandin F receptor, a G-protein coupled receptor, on smooth muscle cells, thereby resulting in smooth muscle contractions. When administered intramuscularly on gravid subjects, this agent induces myometrium contractions, thereby initiating luteolysis and consequently parturition. Furthermore, carboprost's action on vascular smooth muscle and gastrointestinal tract sphincters leads to raised blood pressure and induces vomiting or diarrhea, respectively.
|
|
FDA_UNII_Code |
7B5032XT6O
|
|
Has_Salt_Form | ||
in_subset | ||
label |
Carboprost
|
|
Legacy Concept Name |
Carboprost
|
|
Preferred_Name |
Carboprost
|
|
prefixIRI |
NCIT:C61662
|
|
prefLabel |
Carboprost
|
|
Semantic_Type |
Pharmacologic Substance
|
|
UMLS_CUI |
C0007047
|
|
subClassOf |
Add comment
Delete | Subject | Author | Type | Created |
---|---|---|---|---|
No notes to display |
Create mapping